1600

525 R'c'd PCT/PTO 1 0 JUL 2002

Docket No.: 50179-081

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of   :

John David BENTLEY, et al. :

Serial No.: 09/555,275   :   Group Art Unit: 1618

Filed: May 26, 2000   :   Examiner: T. Washington

For: METHOD OF DESIGNING AGONISTS AND ANTAGONISTS TO IGF RECEPTOR

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Washington, DC 20231

Sir:

Attached is a copy of the Filing Receipt received from the U.S. Patent and Trademark Office in the above-referenced application. It is noted that the name of the sixth Inventor and the Title are incorrect.

Attached is a copy of the Declaration and Power of Attorney received from the U.S. Patent and Trademark Office, which evidences that the correct name of the Inventor should read: **Lynne Jean Lawrence** . The Title should read: **Method of designing agonists to igf receptor.** It is requested that a corrected filing receipt be issued.

Respectfully submitted,

MCDERMOTT, WILL & EMERY

Kelli N. Watson
Registration No. 47,170

600 13th Street, N.W.
Washington, DC 20005-3096
(202)756-8000 KNW:MWE
Facsimile: (202)756-8087
Date: July 8, 2002

10

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/555,275	08/30/2001	1618	1334	50179-081	58	33	

CONFIRMATION NO. 9040

McDermott Will & Emery
600 13th Street NW
Washington, DC 20005-3096

FILING RECEIPT

OC000000007951270

Date Mailed: 04/25/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

John David Bentley, Macedon, AUSTRALIA;
Paul Alexander Tulloch, Denmark, AUSTRALIA;
Leah Jane Cosgrove, Somerton Park, AUSTRALIA;
Maurice John Frenkel, South Caulfield, AUSTRALIA;
Thomas Peter John Garrett, Brunswick, AUSTRALIA;
Lynne Jean Lawrence, Brunswick, AUSTRALIA;
Meizhen Lou, Scoresby, AUSTRALIA;
George Oscar Lovrecz, North Balwyn, AUSTRALIA;
Colin Wesley Ward, Carlton, AUSTRALIA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/AU98/00998 11/27/1998

Foreign Applications

AUSTRALIA PP 0585 11/27/1997
AUSTRALIA PP 2598 03/25/1998

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

Title

Method od designing agonists and antagonists to igf receptor

Preliminary Class

435

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).